Aimei Health Technology Co Ltd Financials
This page shows Aimei Health Technology Co Ltd (AFJK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Aimei Health Technology Co Ltd reported $2.6M in net income in fiscal year 2024.
Aimei Health Technology Co Ltd held $28K in cash against $0 in long-term debt as of fiscal year 2024.
Aimei Health Technology Co Ltd had 2M shares outstanding in fiscal year 2024. This represents an increase of 0.0% from the prior year.
AFJK Income Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | -$130K-212.8% | -$42K+89.9% | -$413K | N/A | -$200K+35.3% | -$309K-101.2% | -$154K | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Net Income | $352K-17.2% | $425K+130.1% | $185K | N/A | $744K+22.1% | $609K-19.4% | $756K | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AFJK Balance Sheet
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $45.5M+2.0% | $44.6M+2.2% | $43.6M-40.9% | $73.8M+1.4% | $72.8M+1.2% | $71.9M+0.9% | $71.3M+1.1% | $70.5M |
| Current Assets | $25K-44.1% | $45K+456.4% | $8K-73.6% | $30K-75.5% | $124K-39.4% | $204K-57.5% | $481K-17.2% | $581K |
| Cash & Equivalents | $3K+39.3% | $2K-70.9% | $7K-74.0% | $28K-72.8% | $104K-34.3% | $158K-61.9% | $414K-28.8% | $581K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $48.9M+3.1% | $47.4M+3.1% | $46.0M-38.9% | $75.3M+2.3% | $73.6M+1.5% | $72.5M+1.3% | $71.6M+1.4% | $70.6M |
| Current Liabilities | $2.8M+25.3% | $2.2M+31.3% | $1.7M+106.3% | $817K+254.0% | $231K+107.5% | $111K+41.7% | $78K+215.9% | $25K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$3.4M-20.3% | -$2.9M-20.8% | -$2.4M-60.3% | -$1.5M-85.3% | -$797K-33.5% | -$597K-107.4% | -$288K-114.5% | -$134K |
| Retained Earnings | -$3.4M-20.3% | -$2.9M-20.8% | -$2.4M-60.3% | -$1.5M-85.3% | -$797K-33.5% | -$597K-107.3% | -$288K-114.4% | -$134K |
AFJK Cash Flow Statement
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | -$224K | N/A | N/A | N/A | -$167K | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | $30.8M | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | -$30.6M | N/A | N/A | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | $31.3M | N/A | N/A | N/A | N/A | N/A |
AFJK Financial Ratios
| Metric | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q3'25 | Q4'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 0.8%-0.2pp | 0.9%+0.5pp | 0.4% | N/A | 1.0%+0.2pp | 0.9%-0.2pp | 1.1% | N/A |
| Current Ratio | 0.01-0.0 | 0.02+0.0 | 0.00-0.0 | 0.04-0.5 | 0.54-1.3 | 1.84-4.3 | 6.13-17.3 | 23.38 |
| Debt-to-Equity | -14.22+2.4 | -16.58+2.8 | -19.42+31.6 | -50.99+41.3 | -92.34+29.2 | -121.50+127.2 | -248.71+277.7 | -526.41 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$1.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Financial Health Signals
Financial strength trend (9 signals). 7-9 = strong, 0-3 = weak.
Operating cash flow vs net income. Above 1.0x = cash-backed earnings.
Similar Companies
Frequently Asked Questions
Is Aimei Health Technology Co Ltd profitable?
Yes, Aimei Health Technology Co Ltd (AFJK) reported a net income of $2.6M in fiscal year 2024.
What is Aimei Health Technology Co Ltd's operating cash flow?
Aimei Health Technology Co Ltd (AFJK) generated -$672K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Aimei Health Technology Co Ltd's total assets?
Aimei Health Technology Co Ltd (AFJK) had $73.8M in total assets as of fiscal year 2024, including both current and long-term assets.
How many shares does Aimei Health Technology Co Ltd have outstanding?
Aimei Health Technology Co Ltd (AFJK) had 2M shares outstanding as of fiscal year 2024.
What is Aimei Health Technology Co Ltd's current ratio?
Aimei Health Technology Co Ltd (AFJK) had a current ratio of 0.04 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Aimei Health Technology Co Ltd's debt-to-equity ratio?
Aimei Health Technology Co Ltd (AFJK) had a debt-to-equity ratio of -50.99 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aimei Health Technology Co Ltd's return on assets (ROA)?
Aimei Health Technology Co Ltd (AFJK) had a return on assets of 3.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Aimei Health Technology Co Ltd's cash runway?
Based on fiscal year 2024 data, Aimei Health Technology Co Ltd (AFJK) had $28K in cash against an annual operating cash burn of $672K. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Aimei Health Technology Co Ltd's debt-to-equity ratio negative or unusual?
Aimei Health Technology Co Ltd (AFJK) has negative shareholder equity of -$1.5M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Aimei Health Technology Co Ltd's Piotroski F-Score?
Aimei Health Technology Co Ltd (AFJK) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.
Are Aimei Health Technology Co Ltd's earnings high quality?
Aimei Health Technology Co Ltd (AFJK) has an earnings quality ratio of -0.26x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.